Agonistic properties of alniditan, sumatriptan and dihydroergotamine on human 5-HT(1B) and 5-HT(1D) receptors expressed in various mammalian cell lines

British Journal of Pharmacology

Volumn 123, Issue 8, 1998, Pages 1655-1665

  Lesage, Anne S ^a   Wouters, Ria ^a   Van Gompel, Paul ^a   Heylen, Lieve ^a   Vanhoenacker, Peter ^b   Haegeman, Guy ^b   Luyten, Walter H M L ^a   Leysen, Josée E ^a  

^a JANSSEN RESEARCH FOUNDATION   (Belgium)

^b GHENT UNIVERSITY   (Belgium)

Author keywords

5 HT(1B); 5 HT(1D); Alniditan; Dihydroergotamine; Migraine; Signal transduction; Sumatriptan; Therapeutics

Indexed keywords

ADENYLATE CYCLASE; ALNIDITAN; BUTYRIC ACID; CYCLIC AMP; DIHYDROERGOTAMINE; FORSKOLIN; ISOPRENALINE; OCAPERIDONE; RISPERIDONE; RITANSERIN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SUMATRIPTAN;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CELL LINE; CONTROLLED STUDY; DRUG POTENCY; EMBRYO; ENZYME ACTIVATION; GLIOMA CELL; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RECEPTOR DENSITY;

ADENYLATE CYCLASE; ANIMALS; BENZOPYRANS; CELL LINE; CELL MEMBRANE; CLONING, MOLECULAR; DIHYDROERGOTAMINE; HUMANS; LIGANDS; MICE; PROPYLAMINES; PYRIMIDINES; RATS; RECEPTORS, SEROTONIN; SEROTONIN AGONISTS; SIGNAL TRANSDUCTION; SUMATRIPTAN; VASOCONSTRICTOR AGENTS;

EID: 0031953613     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701766     Document Type: Article

References (36)

1. ANNUNZIATO, A.T., FRADO, L.L., SEALE, R.L. & WOODCOCK, C.L. (1988). Treatment with butyrate inhibits the complete condensation of interphase chromatin. Chromosoma, 96, 132-13.
2. ARANDA, A., TORO, M.J., USERA, F. & PASCUAL, A. (1990). Regulation by butyrate of the cAMP response to cholera toxin and forskolin in pituitary GH1 cels. Eur. J. Biochem., 187, 683-689.
3. BOFFA, L.C., VIDALI, G. MANN, R.S. & ALLFREY, V.G. (1978). Suppression of histone deacetylation in vivo and in vitro by sodium butyrate. J. Biol. Chem., 253, 3364-3366.
4. 1Dβ-receptor mRNA by in situ hybridisation in guinea-pig brain and trigeminul ganglia. Eur. Neuropsychopharmacol., 6, S4-71.
5. BUZZI, M.G. & MOSKOWITZ, M.A. (1990). The anti-migraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br. J. Pharmacol., 99, 202-206.
6. BUZZI, M.G., MOSKOWITZ, M.A. & HEATH, H.H. (1991). Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology, 30, 1193-1200.
7. COCKETT, M.I., BEBBINGTON, C.R. & YARRANTON, G.T. (1990). High level expression of tissue inhibitor of metalloproteinases in Chinese hamster ovary cells using glutamine synthetase gene amplification. Biotechnology, 8, 662-667.
8. CULLEN, B.R. (1987). Use of eukaryotic expression technology in the functional analysis of cloned genes. Meth. Enzymol., 152, 684-704.
9. DATTI, A. & DENISS, J.W. (1993). Regulation of UDP-Glc-NAc:Gal beta 1-3GalNAc-R beta 1-6-N-acetylglucosaminyltransferase (GlcNAc to GalNAc) in Chinese hamster ovary cells. J. Biol. Chem., 268, 5409-5416.
10. GOADSBY, P.J. & EDVINSSON, L. (1993). The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in man and cat. Ann. Neurol., 33, 48-56.
11. GOADSBY, P.J., ZAGAMI, A.S. & LAMBERT, G.A. (1991). Neuronal processing of craniovascular pain: a synthesis of the central structures involved in migraine. Headache, 31, 365-371.
12. GOLDBERG, Y.P., LEANER, V.D. & PARKER, M.I. (1992). Elevation of large-T antigen production by sodium butyrate treatment of SV40-transformed WI-38 fibrobiasts. J. Cell. Biochem., 49, 74-81.
13. GOLDSTEIN, J., DAHLÖF, C.G.H., DIENER, H.-C., OLESEN, J., SCHELLENS, R., SENARD, J.M., SIMARD, D. & STEINER, T.J. (1996). Alniditan in the acute treatment of migraine attacks: a subcutaneous dose-finding study. Cephalalgia, 16, 497-502.
14. GORMAN, C.M. & HOWARD, B.H. (1983). Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucl. Acids Res., 11, 7631-7649.
15. HAMEL, E., FAN, E., LINVILLE, D., TING, V., VILLEMURE, J.G. & CHIA,L.S. (1993a). Expression of mRNA for the serotonin 5-hydroxytryptamine 1Dbeta receptor subtype in human and bovine cerebral arteries. Mol. Pharmacol., 44, 242-246.
16. 1 receptors mediating contraction in bovine cerebral arteries: a model for human cerebrovascular '5-HT1D beta' receptors. Eur. J. Pharmacol., 242, 75-82.
17. 3H-labeled R091274 at high specific activity. In JRF Non-Clinical Pharmacokinetics Report, Janssen Pharmaceutica, N99382.
18. KENAKIN, T.P. (1993). Drug-receptor theory. In Pharmacologic Analysis of Drug-Receptor Interaction, ed. Kenakin, T.P. pp.1 39. New York: Raven Press.
19. KRUH, J. (1982). Effects of sodium butyrate, a new pharmacological agent on cells in culture. Mol. Cell. Biochem., 42, 65-82.
20. 3H]alniditan. Mol. Pharmacol., 50, 1567-1580.
21. LLEONART, R., NÄF, D., BROWNING, H. & WEISSMANN, C. (1990). A novel, quantitative bioassay for type I interferon using a recombinant indicator cell line. Biotechnology, 8, 1263-1267.
22. 1D receptor in the action of sumatriptan. Eur. J. Pharmacol. Mol. Pharmacol. Section, 227, 99-102.
23. 1D subtype. Naunyn-Schmiedeberg's Arch. Pharmacol., 342, 371-377.
24. MOSKOWITZ, M.A. (1992). Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine. Trends Pharmacol. Sci., 13, 307-311.
25. MOSKOWITZ, M.A. & CURTER, F.M. (1993). Sumatriptan, a receptor targeted treatment for migraine. Ann. Rev. Med., 44, 145-154.
26. 1Dβ receptor gene. Biochem. Pharmacol., 50, 1651-1658.
27. PEROUTKA, S.J. (1993). 5-Hydroxytryptamine receptor subtypes and the pharmacology of migraine. Neurology, 43, S34-38.
28. PRASAD, K.N. & SINHA, P.K. (1976). Effects of sodium butyrate on mammalian cells in culture: a review. In Vitro, 12, 125-132.
29. 1Dα serotonin receptor gene expression in trigcminal ganglia: implications for anti-migraine drug development. Proc. Natl. Acad. Sci. U.S.A., 91, 3666-3669.
30. SEALY, L. & CHALKLEY, R. (1978). The effect of sodium butyrate on histone modification. Cell. 14, 115-121.
31. SHEPHEARD, S.L., WILLIAMSON, D.J., WILLIAMS, J., HILL, R.G. & HARGREAVES, RI (1995). Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudatus of rats. Neuropharmacology, 34, 255-261.
32. VAN DE WATER, A., D'AUBIOUL, J., VAN GERVEN, W., VAN AMMEL, K. & DE CLERCK, E. (1995). Selective vasoconstriction by alniditan in the carotid vascular bed of anaesthetized dogs. Eur. J. Pharmacol., 299, 127-137.
33. 1D agonists. Bioorg. Mcd. Chem. Lett., 5, 2649-2654.
34. VANHOENACKER, P., GOMMEREN, W., LUYTEN, W.H.M.L., LEYSEN, J.E. & HAEGEMAN, G. (1997). Stable, high-level expression of human serotonin receptors in L929 cells using an inducible expression system. Receptors Channels, (in press).
35. 1A receptors occupied by 5-HT or 8-OH-DPAT to adenylate cyclase. Naunyn-Schmiedeberg's Arch. Pharmacol., 346, 367-374.
36. 1Dβ receptors stably expressed in murine fibroblasts: inhibition of adenylate cyclase and elevation of intracellular calcium concentrations via pertussis toxin sensitive G-protein(s). Mol. Pharmacol., 44, 575-582.